🇺🇸 FDA
Patent

US 12404508

Ketohexokinase (KHK) iRNA compositions and methods of use thereof

granted A61KA61K47/02A61K47/549

Quick answer

US patent 12404508 (Ketohexokinase (KHK) iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K47/02, A61K47/549